Related Experiment Video
Updated: Feb 5, 2026

Tissue-Engineered Graft for Circumferential Esophageal Reconstruction in Rats
Published on: February 10, 2020
What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
Ramon Andrade De Mello1, Luis Castelo-Branco1, Pedro Castelo-Branco1
1From the Department of Biomedical Sciences and Medicine, Division of Oncology, University of Algarve, Faro, Portugal; Algarve Biomedical Center, Campus Gambelas, Faro, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Research Centre, Division of Medical Oncology, Hospital São Mateus, NOHC Clinic, Fortaleza, CE, Brazil; Algarve Hospital and University Center, Department of Oncology, Faro, Portugal; Portuguese Public Health School, Nova University, Lisbon, Portugal; Centre for Biomedical Research, University of Algarve, Faro, Portugal; Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal; Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal; Academic Medical Center Amsterdam, Center for Experimental Molecular Medicine, Amsterdam, The Netherlands; and the Division of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Abstract:
Esophageal cancer and gastric cancer are aggressive diseases for which treatment approaches are facing a new era. Some molecular pathways, such as VEGF, EGFR, fibroblast growth factor receptor, PIK3CA, and PARP-1, have been studied, and novel targeted drugs are presumed to be developed in the near future. From The Cancer Genome Atlas report, 80% of Epstein-Barr virus tumors and 42% of tumors with microsatellite instability have PIK3CA mutations, suggesting that this pathway could be reevaluated as a possible target for new systemic treatment of gastric cancer. Notably, higher PARP-1 expression can be found in gastric cancer, which might be related to more advanced disease and worse prognosis. In addition, PD-L1 expression, high microsatellite instability, and mismatch repair deficiency can be found in gastric cancer, thus suggesting that immunotherapy may also play a role in those patients. We discuss trends related to the potential of novel therapies for patients with esophageal and gastric cancers in the near future.
Insights
Novel targeted therapies are emerging for esophageal and gastric cancers. Research highlights PIK3CA mutations and PARP-1 expression as potential targets, alongside immunotherapy for specific patient groups.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Esophageal and gastric cancers are aggressive malignancies with evolving treatment landscapes.
- Several molecular pathways, including VEGF, EGFR, FGFR, PIK3CA, and PARP-1, are implicated in these cancers.
- Emerging research suggests potential for novel targeted drugs and immunotherapies.
Purpose of the Study:
- To review current trends and future potential of novel therapies for esophageal and gastric cancers.
- To explore the significance of specific molecular pathways (PIK3CA, PARP-1) and biomarkers (PD-L1, MSI, dMMR) in gastric cancer treatment.
- To discuss the implications of these findings for systemic treatment strategies.
Main Methods:
- Review of The Cancer Genome Atlas (TCGA) report findings.
- Analysis of molecular pathway alterations in esophageal and gastric cancers.
- Discussion of biomarker expression (PD-L1, MSI, dMMR) and their therapeutic relevance.
Main Results:
- PIK3CA mutations are prevalent in Epstein-Barr virus-positive and microsatellite instability-high gastric tumors.
- Elevated PARP-1 expression in gastric cancer correlates with advanced disease and poorer prognosis.
- PD-L1 expression, high microsatellite instability, and mismatch repair deficiency indicate potential for immunotherapy.
Conclusions:
- PIK3CA pathway warrants reevaluation as a therapeutic target for gastric cancer.
- PARP-1 expression levels may serve as a prognostic indicator in gastric cancer.
- Immunotherapy holds promise for a subset of gastric cancer patients with specific biomarkers.
Related Concept Videos
Expected Value
Determination of Expected Frequency
Esophageal Varices-I: Introduction
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Gastric Emptying
Esophageal Perforation-I: Introduction
The location of esophageal perforation can vary, occurring anywhere along the esophagus....

